Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 1,900,000 shares, a decrease of 15.2% from the June 30th total of 2,240,000 shares. Based on an average daily volume of 950,400 shares, the short-interest ratio is currently 2.0 days.
Matinas BioPharma Stock Performance
Matinas BioPharma stock opened at $0.17 on Tuesday. The stock has a market cap of $41.39 million, a P/E ratio of -1.38 and a beta of 1.70. Matinas BioPharma has a 52 week low of $0.11 and a 52 week high of $0.89.
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.03) EPS for the quarter.
Institutional Investors Weigh In On Matinas BioPharma
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Recommended Stories
- Five stocks we like better than Matinas BioPharma
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Survey: Top 175 Fittest Retirement Locations in America
- Earnings Per Share Calculator: How to Calculate EPS
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- When to Sell a Stock for Profit or Loss
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.